⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019022 | 0.91 | — | — | |
| SCHEMBL11110360 | 0.88 | CA2 (0.39) | — | |
| SCHEMBL17868156 | 0.88 | CA2 (0.39) | — | |
| SCHEMBL1660042 | 0.80 | — | — | |
| SCHEMBL10457263 | 0.79 | CA2 (0.43) | — | |
| SCHEMBL10405537 | 0.79 | CA2 (0.39) | — | |
| SCHEMBL1803985 | 0.78 | — | — | |
| SCHEMBL11147913 | 0.76 | CA2 (0.48) | — | |
| SCHEMBL8069056 | 0.76 | CA2 (0.48) | — | |
| SCHEMBL30041571 | 0.76 | CA2 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | claimed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | claimed |
| CN-105283454-B | Quinazoline and azepine quinazoline as RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR access double inhibitor | ASANA BIOSCIENCES, LLC (US) | 2019-10-29 | — | — | CN | claimed |
| WO-2025059027-A1 | CYCLOPENTA[E]PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS MALT1 INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-111247152-B | Cyclic iminopyrimidine derivatives as kinase inhibitors | 璧辰医药技术股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORPORATION (CA) | 2022-08-11 | — | — | US | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254680-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| CN-114026073-A | Quinazolin-4-one derivatives for the treatment of BRAF related diseases and disorders | ARRAY生物制药公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |